Guangdong Zhuotai Pharmaceutical Co., Ltd. was established in June 2021. It is a biomedical green manufacturing enterprise focused on synthetic biology technology, primarily engaged in researching and developing medicines and medical aesthetic peptides derived from microbial fermentation to address unmet clinical needs. Currently, the company has established a biosynthetic enzyme design platform guided by machine learning algorithms and a high-performance cell casting factory, capable of producing more than one metric ton. They have also designed and modified over 60 biosynthetic gene clusters and more than 10 chassis cells, according to various metabolic pathways. In addition, the company has designed and completed over 20 recombinant genetic engineering strains of pharmaceutical and medical aesthetic peptides (intermediates) from scratch. Currently, the company mainly produces GLP-1 series long-acting molecular peptides, TRZ, TRN, TRU, EK enzyme, C enzyme, T332 enzyme, and other industrial mass-produced products.

The company has built multiple functional R&D laboratories, encompassing molecular biology, genetic recombinant fermentation, extraction and separation, purification, chemical synthesis, quality analysis, and testing, along with a complete industrial-scale pilot production line. The company's current product pipeline includes innovative biological drugs and biosimilar drugs, aimed at various chronic diseases, mainly through fermentation and semi-synthetic products.